CytoMed Therapeutics (GDTC) Fundamental Analysis: Revenue, Earnings & Valuation

0.78 / 10

Underperform

Fundamental assessment: 0.8/10 points to poor condition. Positive attributes: Interest coverage ratio (EBIT / Interest expense) (%) and Current assets turnover ratio, balanced by issues in Accounts receivable turnover ratio and Fixed assets turnover ratio. Concluding perspective: defensive.

Analysis Checks(4/7)

Accounts receivable turnover ratio

Value0.25

Score1/3

Weight28.61%

1M Return-1.07%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight49.62%

1M Return-1.92%

Current assets turnover ratio

Value0.07

Score2/3

Weight19.74%

1M Return-0.73%

Fixed assets turnover ratio

Value0.09

Score1/3

Weight32.77%

1M Return-1.26%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.02

Score2/3

Weight19.72%

1M Return-0.73%

Cost of sales ratio (%)

Value71.88

Score2/3

Weight22.24%

1M Return-0.84%

Current ratio

Value5.17

Score3/3

Weight-72.71%

1M Return2.55%

Is GDTC fundamentally strong?

GDTC scores 0.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -50.08% ROE, -1231.97% net margin, -3.82 P/E ratio, 2.22 P/B ratio, and -64.20% earnings growth, these metrics solidify its Underperform investment rating.